Anzeige
Mehr »
Login
Donnerstag, 03.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Warum Almonty Industries zum Schlüsselplayer für NATO-Staaten wird
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CVT6 | ISIN: US1420381089 | Ticker-Symbol:
NASDAQ
02.04.25
22:00 Uhr
0,861 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CARIBOU BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
CARIBOU BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur CARIBOU BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.03.Caribou Biosciences, Inc. (NASDAQ:CRBU) CEO Rachel E. Haurwitz Acquires 20,000 Shares2
17.03.Caribou Biosciences CEO Rachel E. Haurwitz kauft Aktien im Wert von 20.400 US-Dollar2
10.03.Caribou Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
10.03.Caribou Biosciences, Inc.: Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update580-- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 -- -- Advancing four clinical programs for hematologic malignancies and autoimmune diseases -- -- $249.4...
► Artikel lesen
10.03.Caribou Biosciences, Inc. - 10-K, Annual Report3
10.03.Caribou Biosciences, Inc. - 8-K, Current Report1
13.01.Caribou Biosciences, Inc. - 8-K, Current Report-
CARIBOU BIOSCIENCES Aktie jetzt für 0€ handeln
13.01.Caribou Biosciences, Inc.: Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025143-- CB-010 GALLOP Phase 1 trial initiated in lupus -- -- CB-012 AMpLify Phase 1 trial in r/r AML completes dose level 3 with no DLTs; enrolling patients at dose level 4 -- -- CB-010 ANTLER 2L LBCL...
► Artikel lesen
08.01.Analysts Offer Predictions for CRBU FY2029 Earnings8
07.01.Bank of America Lowers Caribou Biosciences (NASDAQ:CRBU) Price Target to $11.0010
02.01.Caribou Biosciences appoints Sri Ryali as CFO1
02.01.Caribou Biosciences, Inc. - 8-K, Current Report-
16.12.24Caribou Biosciences, Inc. (NASDAQ:CRBU) Short Interest Update4
06.11.24Caribou Biosciences, Inc. - 8-K, Current Report5
12.08.24Caribou Biosciences, Inc.: Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer247-- Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies -- BERKELEY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE)...
► Artikel lesen
03.06.24Caribou Biosciences, Inc.: Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting284-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER...
► Artikel lesen
04.04.24Caribou Biosciences, Inc.: Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus241-- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial safety...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1